Familial hypercholesterolemia and cardiovascular disease in older individuals

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCOUTINHO, Elaine R.
dc.contributor.authorMINAME, Marcio H.
dc.contributor.authorROCHA, Viviane Z.
dc.contributor.authorBITTENCOURT, Marcio S.
dc.contributor.authorJANNES, Cinthia E.
dc.contributor.authorTADA, Mauricio T.
dc.contributor.authorLIMA, Isabella R.
dc.contributor.authorSALGADO FILHO, Wilson
dc.contributor.authorCHACRA, Ana P.
dc.contributor.authorPEREIRA, Alexandre C.
dc.contributor.authorKRIEGER, Jose E.
dc.contributor.authorSANTOS, Raul D.
dc.date.accessioned2021-04-15T19:45:31Z
dc.date.available2021-04-15T19:45:31Z
dc.date.issued2021
dc.description.abstractBackground and aims: Familial hypercholestemlemia (FH) is characterized by high LDL-cholesterol (LDL-C) and early atherosclerotic cardiovascular disease (ASCVD). With a lipid lowering therapy (LLT), most individuals with FH may have a longer ASCVD-free survival. However, there is scant data about older individuals with FH. Methods: We compared characteristics of genetically defined FH older individuals with age-matched non-FH counterparts. Results: From 4111 genotyped individuals, 462 older than 60 years were included (198 positive and 264 negative for FH variants). There were no differences regarding median age [%25; 75%] 66.0 (62.0; 71.0) and 66.0 (62.2; 71.0) years, p = 0.68 for FH and non-FH, respectively. In both groups, there was a higher frequency of females, however, there were more males in the FH group 37.4% vs. 24.2%, p = 0.002. No differences were seen between FH and non-FH in LLT use: 88.5% vs. 91.5%, p = 0.29. Despite a longer LLT duration in FH patients (with 11.0 (7.0; 20.0) vs. 7.0 (3.0; 13.0) years, p < 0.001), treatment was started late in both groups: at 54.0 (47.0; 61.0) and 59.0 (52.0; 64.0) years, p < 0.001, in FH and non-FH, respectively. FH had greater frequencies of previous and early ASCVD (40.9% vs. 27.3%, p = 0.002, and 22.2% vs. 9.0%, p < 0.001). In FH, male sex [HR (95%C01 2.67 (1.50-4.73), p = 0.001, and LLT onset age 0.96 (0.93-0.99), p = 0.009, were independently associated with ASCVD. Conclusions: Among hypercholesterolemic older individuals participating in a cascade screening program, the genetic diagnosis of FH was associated with higher ASCVD rates, emphasizing the relevance of a monogenic defect as the cause of long-lasting hypercholesterolemia and ASCVD risk, particularly in men.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipConselho Nacional de Pesquisa e Desenvolvimento Tecnologico, Brazil, (CNPq)National Council for Scientific and Technological Development (CNPq) [303734/2018-3]
dc.description.sponsorshipMinisterio da Saude (PROADI-SUS) [SIPAR: 25000.180.672/2011-81]
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Esado de Sao Paulo, Sao Paulo, Brazil [2013/17,368-0]
dc.description.sponsorshipSociedade Hospital Samaritano
dc.identifier.citationATHEROSCLEROSIS, v.318, p.32-37, 2021
dc.identifier.doi10.1016/j.atherosclerosis.2020.12.012
dc.identifier.eissn1879-1484
dc.identifier.issn0021-9150
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/39781
dc.language.isoeng
dc.publisherELSEVIER IRELAND LTDeng
dc.relation.ispartofAtherosclerosis
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright ELSEVIER IRELAND LTDeng
dc.subjectFamilial hypercholesterolemiaeng
dc.subjectCardiovascular diseaseeng
dc.subjectOlder individualseng
dc.subjectAgeingeng
dc.subjectMonogenic diseaseeng
dc.subjectAtherosclerosiseng
dc.subjectCholesteroleng
dc.subjectStatinseng
dc.subject.othergender-differenceseng
dc.subject.otherheart-diseaseeng
dc.subject.otherriskeng
dc.subject.otheratherosclerosiseng
dc.subject.otherassociationeng
dc.subject.othereventseng
dc.subject.otheradultseng
dc.subject.wosCardiac & Cardiovascular Systemseng
dc.subject.wosPeripheral Vascular Diseaseeng
dc.titleFamilial hypercholesterolemia and cardiovascular disease in older individualseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus13
hcfmusp.contributor.author-fmusphcELAINE DOS REIS COUTINHO
hcfmusp.contributor.author-fmusphcMARCIO HIROSHI MINAME
hcfmusp.contributor.author-fmusphcVIVIANE ZORZANELLI ROCHA GIRALDEZ
hcfmusp.contributor.author-fmusphcMARCIO SOMMER BITTENCOURT
hcfmusp.contributor.author-fmusphcCINTHIA ELIM JANNES LEPSKI
hcfmusp.contributor.author-fmusphcMAURICIO TERUO TADA
hcfmusp.contributor.author-fmusphcISABELLA RAMOS LIMA
hcfmusp.contributor.author-fmusphcWILSON SALGADO FILHO
hcfmusp.contributor.author-fmusphcANA PAULA MARTE CHACRA
hcfmusp.contributor.author-fmusphcALEXANDRE DA COSTA PEREIRA
hcfmusp.contributor.author-fmusphcJOSE EDUARDO KRIEGER
hcfmusp.contributor.author-fmusphcRAUL DIAS DOS SANTOS FILHO
hcfmusp.description.beginpage32
hcfmusp.description.endpage37
hcfmusp.description.volume318
hcfmusp.origemWOS
hcfmusp.origem.pubmed33450476
hcfmusp.origem.scopus2-s2.0-85099235991
hcfmusp.origem.wosWOS:000613439400005
hcfmusp.publisher.cityCLAREeng
hcfmusp.publisher.countryIRELANDeng
hcfmusp.relation.referenceAlonso R, 2014, J AM COLL CARDIOL, V63, P1983, DOI 10.1016/j.jacc.2014.01.063eng
hcfmusp.relation.referenceAmerican Academy of Family Physicians AdA National Council on the Aging American Academy of Family Physicians ADA National Council on the Aging, 2002, NUTR SCREEN INT RESeng
hcfmusp.relation.referenceAustin MA, 2004, AM J EPIDEMIOL, V160, P421, DOI 10.1093/aje/kwh237eng
hcfmusp.relation.referenceBertakis KD, 2000, J FAM PRACTICE, V49, P147eng
hcfmusp.relation.referenceBesseling J, 2016, J AM COLL CARDIOL, V68, P252, DOI 10.1016/j.jacc.2016.04.054eng
hcfmusp.relation.referenceBesseling J, 2014, ATHEROSCLEROSIS, V233, P219, DOI 10.1016/j.atherosclerosis.2013.12.020eng
hcfmusp.relation.referenceDefesche JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.93eng
hcfmusp.relation.referencedeGoma EM, 2016, CIRC-CARDIOVASC GENE, V9, P240, DOI 10.1161/CIRCGENETICS.116.001381eng
hcfmusp.relation.referenceDewey FE, 2017, NEW ENGL J MED, V377, P211, DOI 10.1056/NEJMoa1612790eng
hcfmusp.relation.referenceEk S, 2015, HEALTH PROMOT INT, V30, P736, DOI 10.1093/heapro/dat063eng
hcfmusp.relation.referenceGallo A, 2017, J CLIN LIPIDOL, V11, P704, DOI 10.1016/j.jacl.2017.03.016eng
hcfmusp.relation.referenceGrundy S.M., J AM COLL CARDIOL, V73eng
hcfmusp.relation.referenceHamczyk MR, 2020, J AM COLL CARDIOL, V75, P919, DOI 10.1016/j.jacc.2019.11.062eng
hcfmusp.relation.referenceHyttinen L, 2008, INT J TECHNOL ASSESS, V24, P228, DOI 10.1017/S0266462308080318eng
hcfmusp.relation.referenceJannes CE, 2015, ATHEROSCLEROSIS, V238, P101, DOI 10.1016/j.atherosclerosis.2014.11.009eng
hcfmusp.relation.referenceJohnson KW, 2018, CUREUS, V10, DOI 10.7759/cureus.2452eng
hcfmusp.relation.referenceKhera AV, 2016, NEW ENGL J MED, V375, P2349, DOI 10.1056/NEJMoa1605086eng
hcfmusp.relation.referenceKhera AV, 2016, J AM COLL CARDIOL, V67, P2578, DOI 10.1016/j.jacc.2016.03.520eng
hcfmusp.relation.referenceLacaze P, 2020, CIRC-GENOM PRECIS ME, V13, DOI 10.1161/CIRCGEN.120.002938eng
hcfmusp.relation.referenceLuirink I.K., 2019, N ENGL J MED, V381eng
hcfmusp.relation.referenceMach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]eng
hcfmusp.relation.referenceMiname MH, 2019, PROG CARDIOVASC DIS, V62, P414, DOI 10.1016/j.pcad.2019.10.003eng
hcfmusp.relation.referenceMiname MH, 2019, JACC-CARDIOVASC IMAG, V12, P1797, DOI 10.1016/j.jcmg.2018.09.019eng
hcfmusp.relation.referenceMundal LJ, 2018, HEART, V104, P1600, DOI 10.1136/heartjnl-2017-312706eng
hcfmusp.relation.referenceMURANO S, 1993, J AM GERIATR SOC, V41, P253, DOI 10.1111/j.1532-5415.1993.tb06702.xeng
hcfmusp.relation.referenceNeil HAW, 1999, ATHEROSCLEROSIS, V142, P105eng
hcfmusp.relation.referencePaquette M, 2017, J CLIN LIPIDOL, V11, P80, DOI 10.1016/j.jacl.2016.10.004eng
hcfmusp.relation.referencePerak AM, 2016, CIRCULATION, V134, P9, DOI 10.1161/CIRCULATIONAHA.116.022335eng
hcfmusp.relation.referencede Isla LP, 2017, CIRCULATION, V135, P2133, DOI 10.1161/CIRCULATIONAHA.116.024541eng
hcfmusp.relation.referencede Isla LP, 2016, J AM COLL CARDIOL, V67, P1278, DOI 10.1016/j.jacc.2016.01.008eng
hcfmusp.relation.referenceRichards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30eng
hcfmusp.relation.referenceRidker PM, 2018, J CLIN LIPIDOL, V12, P958, DOI 10.1016/j.jacl.2018.03.088eng
hcfmusp.relation.referenceSantos RD, 2020, J AM COLL CARDIOL, V75, P565, DOI 10.1016/j.jacc.2019.12.020eng
hcfmusp.relation.referenceSantos RD, 2016, LANCET DIABETES ENDO, V4, P850, DOI 10.1016/S2213-8587(16)30041-9eng
hcfmusp.relation.referenceSharifi M, 2017, ATHEROSCLEROSIS, V263, P405, DOI 10.1016/j.atherosclerosis.2017.05.015eng
hcfmusp.relation.referenceShaw LJ, 2006, J AM COLL CARDIOL, V47, p4S, DOI 10.1016/j.jacc.2005.01.072eng
hcfmusp.relation.referenceShetty P, 2012, LANCET, V379, P1285, DOI 10.1016/S0140-6736(12)60541-8eng
hcfmusp.relation.referenceSilva PRS, 2017, ATHEROSCLEROSIS, V263, P257, DOI 10.1016/j.atherosclerosis.2017.06.917eng
hcfmusp.relation.referenceSLACK J, 1969, LANCET, V2, P1380eng
hcfmusp.relation.referenceTrinder M., 2020, JAMA CARDIOLeng
hcfmusp.relation.referenceTrinder M, 2019, J AM COLL CARDIOL, V74, P512, DOI 10.1016/j.jacc.2019.05.043eng
hcfmusp.relation.referenceVersmissen J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2423eng
hcfmusp.relation.referenceVrablik M, 2017, PHYSIOL RES, V66, pS1, DOI 10.33549/physiolres.933600eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationfe66ed1d-5213-4699-8fdd-d328b3636992
relation.isAuthorOfPublication838d659c-e393-4bc9-93b0-c27a584d7f93
relation.isAuthorOfPublication8231138d-6c9a-41ef-9fa9-a76f229f2293
relation.isAuthorOfPublicatione3193e19-6ede-49dd-bde8-98da34ff70d1
relation.isAuthorOfPublication14da805b-baf8-4c8b-814c-04ccb50904fd
relation.isAuthorOfPublicationd6e71044-2e21-4716-99d5-731bc7f2546d
relation.isAuthorOfPublicationee36d658-62df-4524-9a31-43516d3c4327
relation.isAuthorOfPublicationb1ca5a85-7481-4e28-8510-7e1916fa74f8
relation.isAuthorOfPublication2d850cb2-8f66-45c2-8f7e-5fc4906951a7
relation.isAuthorOfPublication415ce7ca-65c1-4699-b6f4-19dae8b03849
relation.isAuthorOfPublicationa970d450-bcd4-4662-94d6-ad1c6d043b3c
relation.isAuthorOfPublication342e0234-2bff-4c3b-a782-40e80d798912
relation.isAuthorOfPublication.latestForDiscoveryfe66ed1d-5213-4699-8fdd-d328b3636992
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_COUTINHO_Familial_hypercholesterolemia_and_cardiovascular_disease_in_older_individuals_2021.PDF
Tamanho:
901.33 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - ODS/03